| Year |
Citation |
Score |
| 2022 |
Hassan R, Tomar S, Zhang J, Khanal M, Hong J, Venugopalan A, Jiang Q, Sengupta M, Miettinen M, Li N, Pastan I, Ho M. Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumors. Molecular Cancer Therapeutics. PMID 35499461 DOI: 10.1158/1535-7163.MCT-22-0073 |
0.329 |
|
| 2018 |
Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan CM, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, et al. Tumour-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29602801 DOI: 10.1158/1078-0432.CCR-17-3757 |
0.332 |
|
| 2016 |
Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J, Hassan R, Pastan I. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget. PMID 27167198 DOI: 10.18632/oncotarget.9171 |
0.356 |
|
| 2015 |
Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I. Recombinant Immunotoxin with T Cell Epitope Mutations that Greatly Reduce Immunogenicity for Treatment of Mesothelin Expressing Tumors. Molecular Cancer Therapeutics. PMID 26443804 DOI: 10.1158/1535-7163.MCT-15-0532 |
0.347 |
|
| 2010 |
Rothenberg EV, Zhang J, Li L. Multilayered specification of the T-cell lineage fate. Immunological Reviews. 238: 150-68. PMID 20969591 DOI: 10.1111/J.1600-065X.2010.00964.X |
0.302 |
|
| Show low-probability matches. |